However, as methylation of DNA is considered a stable change in DNA that is less susceptible to treatment-induced alterations compared with gene expression, BCL2L1 methylation at cg00300298 may be a better predictor of MCL1 inhibitor response in pediatric cancer (47, 48). The gene discussed is BCL2L1; the disease is cancer.